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Abstract
Background: With the advance of modern irradiation techniques, the role of radiotherapy (RT) for intracranial
meningioma has increased significantly throughout the past years. Despite that tumor’s generally favorable outcome
with local control rates of up to 90% after ten years, progression after RT does occur. In those cases, re-irradiation is
often difficult due to the limited radiation tolerance of the surrounding tissue. The aim of this analysis is to determine
the value of particle therapy with its better dose conformity and higher biological efficacy for re-irradiating recurrent
intracranial meningioma. It was performed within the framework of the “clinical research group heavy ion therapy” and
funded by the German Research Council (DFG, KFO 214).
Methods: Forty-two patients treated with particle RT (protons (n = 8) or carbon ions (n = 34)) for recurrent intracranial
meningioma were included in this analysis. Location of the primary lesion varied, including skull base (n = 31),
convexity (n = 5) and falx (n = 6). 74% of the patients were categorized high-risk according to histology with a WHO
grading of II (n = 25) or III (n = 6), in the remaining cases histology was either WHO grade I (n = 10) or unknown (n = 1).
Median follow-up was 49,7 months.
Results: In all patients, re-irradiation could be performed safely without interruptions due to side effects. No grade IV or V
toxicities according to CTCAE v4.0 were observed. Particle RT offered good overall local control rates with 71% progression-
free survival (PFS) after 12 months, 56,5% after 24 months and a median PFS of 34,3 months (95% CI 11,7–56,9). Histology
had a significant impact on PFS yielding a median PFS of 25,7 months (95% CI 5,8–45,5) for high-risk histology (WHO
grades II and III) while median PFS was not reached for low-risk tumors (WHO grade I) (p= 0,03). Median time to local
progression was 15,3 months (Q1-Q3 8,08–34,6). Overall survival (OS) after re-irradiation was 89,6% after 12 months and
71,4% after 24 months with a median OS of 61,0 months (95% CI 34,2–87,7). Again, WHO grading had an effect, as median
OS for low-risk patients was not reached whereas for high-risk patients it was 45,5 months (95% CI 35,6–55,3).
Conclusion: Re-irradiation using particle therapy is an effective method for the treatment of recurrent meningiomas.
Interdisciplinary decision making is necessary to guarantee best treatment for every patient.
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Background
Intracranial meningiomas are among the most frequent
primary brain tumors [1]. Although benign in principle,
they can afflict severe damage on sensitive intracranial
structures, causing substantial morbidity. Several differ-
ent approaches to the treatment of meningiomas are
established. For safely accessible tumors, neurosurgical
resection is the treatment of choice, however, in critical
locations, e.g. at the skull base, radiation therapy (RT)
has been established as a safe and highly effective treat-
ment modality [2–4].
For asymptomatic low-grade lesions found inciden-
tally, a wait-and-see strategy can be adapted and based
on regular clinical and imaging follow-up [5]. Good
long-term local control rates of up to 95% progression-
free survival (PFS) at five years and 60–80% at 10 years
in separate series can be achieved if the lesion is easily
accessible for complete resection [6]. However, substan-
tial post-operative morbidity can occur if sensitive vas-
cular or neuronal structures are compromised by the
resection, such as is the case with large tumors located
at the skull base if complete resection is sought. On the
other hand, postoperative RT can complement incom-
plete resection and achieve satisfactory results at low
toxicity rates. It is strongly recommended for WHO
grade II/III meningiomas and can be a suitable option
for salvage treatment in case of recurrence after neuro-
surgical resection [6, 7]. Non-surgical treatment options
include stereotactic radiosurgery (SRS) and fractionated
stereotactic radiotherapy (FSRT), achieving local control
rates similar to those of complete surgical resection for
tumors located in regions not accessible to surgery [8].
In some cases, where the preservation of adjoining
radiosensitive tissue is critical or tumor shapes are more
complex, intensity modulated radiotherapy (IMRT) can
deliver higher dose conformity than conventional SRS or
FSRT, achieving excellent local control rates [9]. Particle
therapy, such as proton or carbon ion irradiation, is
characterized by distinct physical and biological proper-
ties. The reduction of integral dose to adjoining healthy
tissue with particle therapy could contribute to the re-
duction of long-term toxicity and is of special interest
where prolonged survival is potentially achievable, as ap-
plies to the treatment of meningiomas [6]. Furthermore,
the higher biological doses that can be delivered by the
use of heavy particles such as carbon ions could improve
tumor control for high-risk histologies [10, 11]. To date,
sparse clinical data is available on particle therapy for
meningiomas. A significant prognostic factor for
progression-free survival (PFS) as well as overall survival
(OS) lies in the histological characteristics of the tumor,
with benign WHO grade I meningiomas yielding signifi-
cantly longer PFS and OS than atypical meningiomas
(WHO grade II) and malignant/anaplastic tumors
(WHO grade III) showing the lowest local control rates
as well as shortest OS [12].
In cases of tumor progression after initial radiotherapy,
treatment options are generally limited. Interdisciplinary
treatment decisions are usually obtained. Re-irradiation
can be indicated in selected cases, depending on the
previous dose distribution, time between primary and
re-irradiation, location and especially on the vicinity to
organs at risk (OAR).
Re-irradiation is generally performed using high-
precision techniques; the characteristics of particle therapy
offer excellent sparing of normal tissue outside the defined
target volume, thus promising a beneficial risk-benefit-
profile. The current analysis was performed to evaluate
toxicity as well as local control and survival after re-
irradiation with protons and carbon ions for recurrent
meningiomas.
Methods
Patient characteristics
Between 2009 and 2013, forty-four patients with recurrent
intracranial meningiomas after having previously received
radiotherapy, were re-irradiated using particle therapy.
Two patients were lost to follow-up. Thus, for our analysis
we took into account forty-two patients. All patients re-
ceived re-irradiation at Heidelberg Ion Therapy Center
(HIT), employing the raster-scanning technique for active
beam delivery developed by Haberer et al. [13]. Thirty-
four patients received carbon ion therapy, whereas eight
patients received proton therapy. Median patient age at
re-irradiation was 54 years (range 18 to 77 years), while
age at primary diagnosis ranged from 12 to 64 years with
a median of 44 years. Tumor location can be divided into
three main categories: convexity, falx and skull base, of
which the skull base was most common (n = 31). Seventy-
four percent of the patients were categorized high-risk
according to histology with a WHO grading of II (n = 25)
or III (n = 6); in the remaining cases histology was either
WHO grade I (n = 10) or unknown (n = 1). Patient charac-
teristics are illustrated in Table 1.
Previous treatment and recurrence
Previous treatment included a number of different
modalities and techniques. All patients, except for two,
had surgery at least once at some point during previous
treatment; in almost all cases a partial resection was
performed, in one case only a biopsy was performed.
Intensity modulated radiotherapy (IMRT) (n = 16) and
conventional 3D-planned RT (3DCRT) (n = 16) were the
most commonly employed techniques with a median
cumulative dose of 52,9 Gy (12,1–62,4 Gy) for IMRT.
Of those patients, only two received less than 50 Gy:
One patient dropped out of treatment after 12,1 Gy
and one patient received a hypofractionated regimen
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of 11 × 3,8 Gy. Median cumulative dose for 3DCRT was
54 Gy (50,5–55,8 Gy). Seven patients received stereotactic
radiosurgery (SRS) at a median dose of 12,1 Gy
(12,0–17,0 Gy) and one patient had received FSRT at a cu-
mulative dose of 58,8 Gy. One patient had previously re-
ceived a radiopeptide therapy with Y-90 DOTATATE at
4,39 Gbq, corresponding to an approximated local dose of
10 Gy, whereas one patient received two consecutive
courses of carbon ion RT due to tumor progression. None
of the patients received any kind of systemic therapy.
All tumor recurrences were confirmed by repeated im-
aging via contrast-enhanced CT or MRI, in 17 cases an
additional FET- and/or DOTATOC-PET was performed
to help treatment planning. In most cases, infield and
field border recurrences were observed (n = 38), only
four cases showed additional outfield growth.
Target volume delineation
For treatment planning, an individual head fixation
mask that guarantees immobilization during RT and
allows for precision dose delivery to a maximum posi-
tioning error of 1–2 mm was individually fitted for
each patient [14, 15]. Correct patient positioning was
verified prior to beam delivery using orthogonal X-rays.
For target volume definition, the treatment planning
CT imaging data was matched to a contrast-enhanced
MRI to allow for a more precise estimate of microscopic
tumor extension. On the T1-weighted sequence, con-
trasted tumor formations were delineated as gross tumor
volume (GTV). Adjoining meningeal enhancement
(dural tail) was included into the clinical target volume
(CTV) and in complex cases with extensive locoregional
spread (e.g. infiltration of bony structures, defects and
changed anatomy due to previous surgery), a safety mar-
gin of 1 mm (benign histology) or 2–3 mm (malignant
histology) was added and adapted at the discretion of
the treating physician to include areas of potential
microscopic spread. In 17 cases, an additional FET- and/
or DOTATOC-PET was performed to further facilitate
target volume definition. GTV equaled CTV in 29
(69,0%) of the cases. Median relative increase in CTV
size was 76,4% (22,7 ml) in the 13 cases where an
additional safety margin was added. An isotropic PTV
margin of 3 mm was added in all cases to compensate
for positioning and technical insecurities, as is standard
procedure for intracranial irradiation at HIT. Details of
resulting target volume sizes are illustrated in Table 2.
Treatment planning
Treatment planning and biological plan optimization
were done utilizing the planning software TRiP [16, 17].
Patients received a median cumulative dose of
Table 1 Patient characteristics
Age at re-irradiation (years)
Mean (SD) 53 13,4
Median (Q1-Q3) 53 47–61
Median (range) 53 18–77
n= %
Gender
male 17 40,5%
female 25 59,5%
Histology
WHO I 10 23,8%
WHO II 25 59,5%
WHO III 6 14,3%
unknown 1 2,4%
Location
skull base 31 73,8%
falx 6 14,3%
convexity 5 11,9%
Karnofsky performance score
≥ 80% 34 81,0%
< 80% 8 19,0%
Previous radiotherapy
IMRT 16 38,1%
3DCRT 16 38,1%
SRS/FSRT 8 19,0%
radiopeptide 1 2,4%
carbon ions 1 2,4%
Recurrence
infield / field border 38 90,5%
outfield 4 9,5%
Particle therapy
protons 8 19,0%
carbon ions 34 81,0%
Table 2 Target volume sizes and treatment planning
parameters.
median (ml) Q1-Q3 mean (ml) std dev (ml)
GTV 18,1 6,7–82,6 51,3 67,9
CTV 48,9 22,5–93,9 82,3 96,3
PTV 75,1 37,1–126,2 102,9 93,6
n= %
Cases with GTV = CTV 29 69,0%
Cases with additional CTV margin 13 31,0%
median Q1-Q3
median absolute increase by CTV 22,7 ml 9,3 ml - 43,1 ml
Median relative increase by CTV 76,4% 35% - 269,5%
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51 Gy(RBE) (range 15–60 Gy(RBE)) of particle therapy at
a median of 19 fractions (range 5–32 fractions). Four of
those patients received particle therapy only as a carbon
ion boost of 15 Gy(RBE) (n = 1) or 18 Gy(RBE) (n = 3), ap-
plied after 50–52 Gy of photon irradiation. For carbon ion
therapy most commonly, a dose per fraction of 3 Gy(RBE)
was applied as well as a dose per fraction of 3,3 Gy in one
case. For proton therapy smaller doses per fraction such
as 1,8 Gy(RBE) or 2,0 Gy(RBE) were used. Treatment was
delivered in 6 daily fractions per week.
Generally, where OAR tolerance permitted, a dose up-
ward of 50 Gy(RBE) for WHO I tumors and upward of
54 Gy(RBE) for higher grade tumors was aimed for.
Coverage by the prescribed dose was optimized for
CTV; focally reduced PTV coverage was accepted to
allow for OAR sparing if necessary. Actual dose
prescription was decided on a case-by-case basis and
was naturally influenced by the dose distribution of
previous radiotherapy and remaining radiotolerance.
Carbon ions were preferred for re-irradiation for their
higher biological effectiveness and the potential benefit
in tumors that had progressed after previous
radiotherapy. Protons were chosen in selected cases
where the moderately hypofractionated approach estab-
lished for carbon ion therapy with a single dose of
3 Gy(RBE) was not preferable or for resulting in an ad-
vantageous dose distribution in individual cases. The ap-
proach of delivering a carbon ion boost of 18 Gy(RBE)
in addition to 50 Gy of photon radiotherapy was applied
for patients treated analogous to the MARCIE-trial, a
phase II trial currently being conducted at our institu-
tion for atypical meningiomas [18]. Table 3 presents an
overview of cumulative doses and fractionation schemes
used for different histologies.
For all patients, documentation of previous radiotherapy
including multi-slice dose distribution was obtained and
carefully correlated with the current clinical situation.
Constraints for OAR, including brain stem and optic
pathway, were set in consideration of the previous cumu-
lative dose received and generally based on the recom-
mendations laid out by Emami et al. [19]. TD 5/5 dose
limits were disregarded in several cases where a clinical
rationale justified that decision (e.g. tumor infiltration or
direct proximity). In those cases, the increased risk of
Table 3 Different fractionation schemes and their absolute frequencies listed by tumor histology. To facilitate comparison between
fractionation schemes equivalent doses in 2 Gy fractions (EQD2) for an assumed α/β of 2 have been calculated.
Histology fractionation cumulative dose (Gy(RBE)) EQD2 (Gy(RBE)) n= median cumulative EQD2 (Gy(RBE))
WHO I C12: 15 × 3 45 56,3 2 52,4
H1: 32 × 1,8 57,6 54,7 2
C12: 17 × 3 51 63,8 1
H1: 29 × 1,8 52,2 49,6 1
C12: 25 × 2 50 50,0 1
C12: 16 × 3 48 60,0 1
H1: 30 × 1,5 45 39,4 1
C12: 12 × 3 36 45,0 1
WHO II C12: 17 × 3 51 63,8 10 60,0
C12 Boost after 50 Gy photon RT: 6 × 3 68 72,5 3
C12: 13 × 3 39 48,8 2
C12: 15 × 3 45 56,3 2
C12: 19 × 3 57 71,3 1
H1: 27 × 2 54 54,0 1
H1: 30 × 1,8 54 51,3 1
H1: 25 × 2 50 50,0 1
C12: 15 × 3,3 49,5 65,6 1
C12: 20 × 3 60 75,0 1
C12: 18 × 3 54 67,5 1
H1: 20 × 2 40 40,0 1
C12 Boost after 50 Gy photon RT: 5 × 3 65 68,8 1
WHO III C12: 17 × 3 51 63,8 3 56,3
C12: 15 × 3 45 56,3 2
C12: 13 × 3 39 48,8 1
El Shafie et al. Radiation Oncology  (2018) 13:86 Page 4 of 12
treatment-associated toxicity was discussed individually
with the patient and a decision was reached with respect
to patient preference and clinical necessity. Parts of the
optic pathway received maximum doses upward of 50 Gy
in a total of 9 cases. An overview of biological doses re-
ceived by OAR is illustrated in Table 4. To compensate
for differences in fractionation, equivalent doses in 2 Gy
fractions (EQD2) for an assumed α/β of 2 for normal
tissue are displayed.
Follow-up
The first follow-up visit was scheduled 6 weeks after
therapy completion with subsequent three-monthly
visits for the first year. After that, twice-yearly visits were
scheduled for an additional period of 2 years, thereafter
once a year. Procedure during follow-up consisted of a
contrast-enhanced MRI-examination as well as a thor-
ough clinical check-up [20]. Symptoms and toxicities
were documented in detail in the patient’s medical rec-
ord and subsequently entered into a prospective research
database maintained at our institution for long-term
systematic follow-up of radiooncological patients [21].
Symptoms were classified according to the Common
Terminology Criteria for Adverse Events (CTCAE) v. 4.0
[22]. New or worsening symptoms were considered
acute and treatment-related toxicities if they occurred
within the first 6 months after radiotherapy and late
toxicities if they occurred after that. Symptoms were
followed up and outcome was judged at last follow-up as
either stable/improved or worsened. Toxicities of grades
I and II according to CTCAE were classified low-grade.
Any de novo symptoms grade III or higher were
classified high-grade, as were any pre-existing symptoms
worsening by at least two CTCAE grades except if
directly attributable to tumor progression.
Statistical analysis
For descriptive baseline analyses, continuous variables are
given as means (SD) and median (quartiles, range where
appropriate) and categorical variables as absolute and
relative frequencies. Overall survival (OS) was calculated
separately from the date of primary diagnosis and from
the date of re-irradiation until death or last observation
during follow-up (censored data). Progression-free sur-
vival (PFS) was determined from the time of the beginning
of radiotherapy until tumor progression or to last observa-
tion or death if none occurred (censored data). OS and
PFS were calculated using the Kaplan-Meier-Method. The
median follow-up time was calculated using the reverse
Kaplan-Meier method [23]. Survival curves for prognostic
factors were compared using a two-sided log-rank test. Since
this was a retrospective exploratory data analysis, p-values
are of descriptive nature. A descriptive p-value of < 0.05 was
considered to indicate statistical significance. All statistical
analyses were performed using the statistics software IBM
SPSS Statistics Version 22 (New York, USA). This study was
approved by the Ethics Committee of the Medical Faculty of
Heidelberg (ref. no.: s-207/2013).
Results
Local tumor control and survival
The reverse Kaplan-Meier estimate for median follow-up
was 49,7 (Q1-Q3 28,3–69,4; 95% CI 29,7–60,6) for
progression-free survival and 50,2 months (Q1-Q3 23,2–
Table 4 Dose statistics (EQD2) for different organs at risk, regarded independently by tumor location: All locations (n = 41), only skull
base tumors (n = 31) and a subgroup of especially complex cases with tumors adjoining to OAR (n = 28)
median mean dose IQR mean mean dose std dev median max dose IQR mean max dose std dev
All locations, n = 41
brain stem 1,1 0,1–3,4 2,5 4,6 21,1 1–37,5 23,1 18,1
optic chiasm 3,5 0–11,7 7,7 10,7 19,6 0,2–35,9 20,4 19,3
left optic nerve 2,9 0–11,3 9,8 15,6 20,3 0,1–43,6 23,9 22,9
right optic nerve 1,7 0,1–9 10,7 18,5 16,1 0,3–44,3 24,0 25,3
Only skull base, n = 31
brain stem 2,0 0,9–3,9 3,4 5,2 31,7 19,9–40,2 31,1 13,9
optic chiasm 5,5 2,7–16 10,3 11,5 23,7 15–41,2 27,2 17,8
left optic nerve 5,9 2,2–21,2 13,7 17,1 29,6 17,7–48,7 32,9 21,1
right optic nerve 4,3 0,8–35,7 14,9 20,5 25,7 11–54,2 32,1 24,9
Complex cases, n = 28
brain stem 2,0 0,9–3,8 3,4 5,2 31,7 20,2–38,4 30,3 12,6
optic chiasm 6,0 2,9–16,6 10,9 11,6 24,6 16,1–40,6 28,1 17,2
left optic nerve 6,1 1,8–23,6 14,5 17,4 29,6 18,6–50,1 34,0 20,9
right optic nerve 2,9 0,8–29,4 14,1 20,1 25,7 12,8–52,4 31,8 24,2
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64,6; 95% CI 42,8–56,1) for overall survival. A
progression-free survival rate (PFS) of 71,0% after
12 months and 56,5% after 24 months could be achieved.
Median PFS for all patients was 34,3 months (Q1-Q3
10,2–70,5; 95% CI 11,7–56,9) (Fig. 1). Histology at primary
diagnosis appeared to be an important prognostic factor
for progression-free survival as well as overall survival
(OS) with a clear distinction between low-risk (WHO
grade I histology) and high-risk tumors (WHO grades II
and III). Histology-adjusted median PFS showed to be
25,7 months (Q1-Q3 10,0–54,0; 95% CI 5,8–45,5) for
high-risk tumors, while for low-risk tumors median PFS
was not reached due to the limited number of events. The
difference in PFS between low-risk and high-risk tumors
was significant (p= 0,03) (Fig. 2). Regarding all three WHO
grades separately, median PFS for grade II meningiomas was
34,3 months (Q1-Q3 10,0–54,0; 95% CI 6,9–61,7) and for
grade III meningiomas 10,2 months (Q1-Q3 5,4–17,1; 95%
CI 0–20,4). While patient numbers are limited in this ana-
lysis, no significant difference in PFS could be detected be-
tween grade II and grade III meningiomas (p= 0,43) (Fig. 3).
Overall survival (OS) after re-RT was 89,6% after
12 months and 71,4% after 24 months with a median overall
survival of 61,0 months (95% CI 34,2–87,7) (Fig. 4a). Calcu-
lated from the date of primary diagnosis, median OS was
238,7 months (Fig. 4b). Again, histology at primary diagnosis
appeared to be an important prognostic factor, albeit statis-
tical significance was not reached (p = 0,05), possibly due to
small sample size. Median OS was not reached in the low-
risk group. One death unrelated to meningioma was docu-
mented in this group. In the high-risk group median OS
was 202,5 months (95% CI 149,3–255,8) (p = 0,05) (Fig. 5).
Regarding all three WHO grades separately, median OS
was significantly better for grade I, compared to both
grades II and III. Median OS was not reached for grade I
and was 238,7 months (95% CI 118,8–358,6) for grade II
(p = 0,04). For grade III median OS was 173,6 (95% CI
0–367,7) (p = 0,02)). There was no significant difference
in OS between grade II and grade III (p = 0,38) (Fig. 6).
Fig. 1 Progression-free survival for patients with recurrent
meningioma regardless of histology after re-irradiation with
particle therapy
Fig. 2 Impact of histology on progression-free survival when
classified as low-risk (WHO grade I) and high-risk (grades II and III).
The difference between the two groups was significant (p = 0,03)
Fig. 3 Impact of histology on progression-free survival regarding all
WHO grades separately: The difference between grades I and III was
significant (p = 0.02) but not between grades II and III (p = 0,43)
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Progression after re-radiotherapy in all cases occurred
as local progression. Median time to progression was
15,3 months (Q1-Q3 8,08–34,6) with tumor progression
occurring within the first 24 months after re-irradiation
in 63% of the cases. In most cases, tumor progression
occurred in-field (n = 10) or at the field border (n = 7).
Five patients developed out-of-field tumor progression
in the form of secondary intracranial meningiomas; of
those cases three also developed in-field progression. In
two cases, the exact site of tumor progression could not
be determined for imaging data was not available at our
institution.
Treatment-related toxicity
All patients were able to complete re-irradiation success-
fully and no interruptions or abortions of treatment due
to acute toxicity were necessary. Exploiting the physical
and biological features of particle irradiation, a high dose
conformity could be achieved in treatment planning,
effectively reducing dose to adjoining OAR with de-
pleted radiotolerance due to previous irradiation (Fig. 7).
No grade IV or V toxicities according to CTCAE v4.0
were observed. Acute toxicity was moderate and
included mostly focal alopecia, fatigue and moderate
skin irritation. In all cases, acute toxicity was regressive
Fig. 4 Overall survival for patients with recurrent meningioma regardless of histology after re-irradiation with particle therapy, calculated from
date of re-irradiation (a) and from date of primary diagnosis (b)
Fig. 5 Impact of histology on overall survival when classified as
low-risk (WHO grade I) and high-risk (grades II and III). While patient
number is limited, statistical significance was not reached (p = 0.05)
Fig. 6 Impact of histology on overall survival regarding all WHO
grades separately: The difference between grades I and III was
significant (p = 0,01) but not between grades II and III (p = 0,30)
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within a maximum of one year after completion of therapy.
Few cases of late toxicity were observed, including pre-
dominantly prolonged fatigue, low grade xerostomia and
intermittent headaches or episodes of nausea (Table 5).
Three cases of radionecrosis were documented: One pa-
tient with an atypical meningioma of the left cerebellar
tentorium was treated with 51 Gy(RBE) carbon ions after
having received 54 Gy adjuvant photon radiotherapy in an
overlapping area, three years prior. Radionecrosis was
symptomatic with blurred vision and dizziness. In addition
to the radionecrosis, the patient developed tumor progres-
sion at the same time and was referred to neurosurgical
resection. In the second case, the patient had received
60 Gy of adjuvant photon radiotherapy after resection of
an anaplastic meningioma of the right sphenoid wing in
2011. He was re-irradiated one year later in 2012 for local
progression, receiving 51 Gy(RBE) carbon ions that he
tolerated well. He developed a radionecrosis of the right
temporal lobe after receiving 40 Gy of another course of
photon irradiation in 2013 for a second anaplastic men-
ingioma of the falx that he developed during follow-up.
The patient was referred to successful neurosurgical
necrosectomy but died 7 months thereafter of tumor pro-
gression. Notably he had also been previously irradiated
for retinoblastoma in 1969. In the third case, radionecrosis
developed after re-irradiation with 51 Gy(RBE) carbon
ions and previous 60 Gy of photon irradiation two years
prior for an anaplastic meningioma of the parieto-
occipital region. Symptoms were mild and did not pro-
gress after corticosteroid administration. They consisted
of slight worsening of pre-existing epilepsy, blurred vision
and headaches.
Symptom response to treatment
Symptoms and neurological status were ascertained
before the beginning of treatment, during treatment as
well as during follow-up. Common symptoms prior to
RT included pain or neuralgia in the head-and-neck
region, neurological symptoms in terms of motor
impairment, hypoesthesia or paresthesia, mostly also in
the facial or head-and-neck region, hearing impairment,
dizziness, seizures and visual impairment. Notably, visual
impairment, mostly diplopia, proved to be among the
most common symptoms prior to radiotherapy. In 24%
Fig. 7 Exemplary treatment plan for re-irradiation of a large recurrent
meningioma of the skull base. A re-irradiation dose of 17 × 3 Gy(RBE)
carbon ions was applied and a dose of 11 × 3,8 Gy photons had been
applied one year earlier in a FSRT-setting. Dose to the directly adjoining
optic chiasm could be reduced to 11,0 Gy(RBE) mean (33,3 Gy(RBE)
max) and dose to the brain stem to 6,5 Gy(RBE) mean (36,3 Gy(RBE)
max). CTV is delineated in red and PTV in blue
Table 5 Acute and late treatment-related toxicity
Acute treatment-related toxicity Late treatment-related toxicity
Side effect low grade (CTCAE I-II) high grade (CTCAE III or higher) low grade (CTCAE I-II) high grade (CTCAE III or higher)
n= % n= % n= % n= %
focal alopecia 14 33,3% 0 0,0% 1 2,4% 0 0,0%
fatigue 11 26,2% 0 0,0% 4 9,5% 0 0,0%
skin irritation 10 23,8% 0 0,0% 1 2,4% 0 0,0%
headache 7 16,7% 0 0,0% 2 4,8% 0 0,0%
nausea 7 16,7% 0 0,0% 2 4,8% 0 0,0%
lymphedema 3 7,1% 0 0,0% 0 0,0% 0 0,0%
mucositis 3 7,1% 0 0,0% 0 0,0% 0 0,0%
xerostomia 2 4,8% 0 0,0% 3 7,1% 0 0,0%
facial pain 1 2,4% 0 0,0% 2 4,8% 0 0,0%
radionecrosis 1 2,4% 2 4,8% 0 0,0% 0 0,0%
dysgeusia 1 2,4% 0 0,0% 0 0,0% 0 0,0%
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of the affected patients, an improvement within a year
after re-irradiation could be achieved. During long-term
follow-up, a total of four patients reported a worsening
of their visual impairment after re-irradiation with par-
ticle therapy. Motor impairment improved or stabilized
in 31% of the affected patients and sensory impairment
in 38%. Overall, few patients reported worsening of their
symptoms during follow-up and second to eye-related
symptoms predominantly motor function was affected.
An overview of the predominant symptoms prior to re-
irradiation and their relative development after re-
irradiation is presented in Table 6. No secondary malig-
nancies in the brain or head-and-neck area were
reported.
Discussion
The present analysis demonstrates that re-irradiation
with particle therapy offers a low toxicity profile; in spite
of the reduced doses in re-irradiation, local control is
relatively high at 71% after 12 months and survival after
re-irradiation is promising.
Recurrences after RT in patients with meningiomas
generally represent a difficult clinical situation; previous
radiotherapy has often fully exhausted the radiation
tolerance of surrounding normal tissue; thus, any add-
itional RT has to be performed using highly advanced
RT modalities. Other treatment alternatives include sur-
gery, however, especially in skull base lesions, the risk of
neurosurgical intervention can be associated with high
rates of treatment-related sequelae [6]. Systemic treat-
ment offers only modest effect: Smaller series on chemo-
therapeutic substances such as Hydroxyurea and
temozolomide offer only limited efficacy, however, can by
associated with significant hematological toxicity [24, 25].
Molecularly targeted substances, such as VEGFR and
EGFR inhibitors have been applied in individual patients
after neuropathological evaluation of marker expression,
however, overall results were poor and no larger series or
randomized trials are available. Moderate results have
been shown in small retrospective series for the angiogen-
esis inhibitor bevacizumab with a median PFS of
18 months although significant toxicity was reported, with
one fifth of the included patients discontinuing therapy
due to toxicity [26]. Comparable results were found for
treatment with sunitinib, a small-molecule tyrosine kinase
inhibitor targeting VEGFR with a reported six-months-
PFS rate (PFS-6) of 42%. However, here again one third of
the included patients required dose reduction and 22%
were removed from the study due to increased toxicity in-
cluding one fatal CNS hemorrhage [27]. An overview of
the limited systemic treatment options for recurrent men-
ingioma has been provided by Kaley and colleagues, who
in 2014 reviewed forty-seven different publications on the
subject and calculated a weighted average PFS-6 of 29%
for WHO grade I meningioma and 26% for WHO grade
II/III meningioma respectively [28].
Thus, in cases of meningioma recurrence after RT
treatment options are limited, and a second course of
RT is discussed frequently when no other alternatives
are available. Although high precision photon RT modal-
ities such as SRS/FSRT and IMRT are widely available by
now, particle therapy still offers several distinct advan-
tages due to its unique physical characteristics that allow
a local dose peak (Bragg Peak) at a variably definable
depth level with very little dose deposition up to and
beyond that point [29]. Over the past years, several plan-
ning studies have shown repeatedly that particle therapy
can deliver higher dose conformity, with maximum dose
Table 6 Predominant symptoms prior to re-irradiation and their relative improvement development during follow-up
Symptoms before particle re-irradiation Symptoms at last follow-up Clinical outcome
Predominant clinical
symptoms
low grade (CTCAE I-II) high grade
(CTCAE III
or higher)
low grade
(CTCAE I-II)
high grade
(CTCAE III or higher)
stable or improvement worsening
n= % n= % n= % n= % n= % n= %
sensory impairment 17 40,5% 1 2,4% 14 33,3% 1 2,4% 16 38,1% 1 2,4%
motor impairment 12 28,6% 3 7,1% 9 21,4% 1 2,4% 13 31,0% 3 7,1%
visual impairment 11 26,2% 6 14,3% 7 16,7% 9 21,4% 12 28,6% 4 9,5%
cognitive impairment 9 21,4% 0 0,0% 5 11,9% 1 2,4% 10 23,8% 0 0,0%
hearing impairment 7 16,7% 3 7,1% 9 21,4% 3 7,1% 10 23,8% 2 4,8%
headaches 6 14,3% 0 0,0% 7 16,7% 0 0,0% 10 23,8% 2 4,8%
seizures 5 11,9% 0 0,0% 4 9,5% 0 0,0% 6 14,3% 1 2,4%
nausea 4 9,5% 0 0,0% 3 7,1% 1 2,4% 8 19,0% 2 4,8%
dizziness 2 4,8% 1 2,4% 3 7,1% 1 2,4% 4 9,5% 2 4,8%
facial pain 2 4,8% 1 2,4% 3 7,1% 1 2,4% 4 9,5% 2 4,8%
fatigue 1 2,4% 0 0,0% 5 11,9% 0 0,0% 9 21,4% 2 4,8%
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applied to the tumor and reduction of medium and low
dose to the surrounding tissue, thus reducing the overall
integral dose and effectively sparing OAR [30–32]. This
has recently and comprehensively been reviewed by De
Ruysscher and colleagues [33]. Particle therapy employ-
ing passive methods of beam delivery has been in use at
several institutions for some time, however the method
of active raster-scanning [13], with which beam delivery
is being conducted at HIT is to date unique and has
proven advantageous over passive beam delivery in
different aspects, since no additional patient-specific
hardware is required for the accurate shaping of dose
distribution, significantly facilitating and accelerating
planning as well as treatment processes [10].
In addition to the abovementioned physical advantages
of particle therapy, heavy ions such as carbon offer
biological benefits attributed to the increased relative
biological effectiveness (RBE) of heavy ion irradiation
[16] and decisively affecting treatment planning and ef-
fective dose calculation. In vitro experiments have
proven the increased cytotoxic effect of carbon ion RT,
yielding different values for the RBE depending on fac-
tors such as linear energy transfer (LET) value and cell
line [34] and showing enhanced cytotoxicity even for
relatively radioresistant cells such as pancreatic cancer
cells with calculated RBE values of up to 4,5 compared
to photon RT [11]. Clinical correlation for this data can
be found in studies that have been conducted for several
tumor entities such as chordoma, skull base chondrosar-
coma as well as adenoid cystic carcinoma, showing
improved local control after irradiation with carbon ions
compared to photon RT [35–37].
Altogether, the abovementioned aspects prove benefi-
cial in treating a recurrent tumor that is in close vicinity
to radiosensitive OAR, especially in a heavily pre-treated
situation, as is the case for the patients in this analysis.
There have been few studies to date that showed the
feasibility and effectiveness of carbon ion RT in the
setting of re-irradiation, showing local tumor control of
up to 92% at 24 months and 64% at 36 months for dif-
ferent tumor entities of the skull base [20] and only
moderate toxicity for recurrent head and neck cancers
with different histologies [38].
For the treatment of meningioma, feasibility of par-
ticle therapy has been proven in past studies, however
the available data focuses mainly on treatment in a
primary or adjuvant setting with no prior course of
RT, usually including only small groups of patients.
Reported survival rates were up to 75% at 5 years
and 63% at 7 years for high-risk meningiomas [39]
and a more recent analysis employing additional
DOTATOC-PET for target volume definition has
shown 100% local control (follow-up 2–22 months)
for WHO grade I meningiomas [10].
Taking into account those results, there is sparse clin-
ical data available on particle therapy for patients with
recurrent meningioma. The abovementioned studies
have reported on smaller patient sub-groups receiving
helical tomotherapy (n = 4) or particle therapy (n = 19)
as re-irradiation yielding local control rates of up to 67%
at 12 months for carbon ion RT [10, 40]. Furthermore, a
series on nineteen patients receiving SRS or FSRT as re-
irradiation for recurrent meningioma has yielded similar
PFS rates and once more proven histology to be the
most important prognostic factor for PFS [41].
Limitations of this present study include its retrospective
character, limited number of patients, as well as relatively
short follow-up. To date, however, there is no other dedi-
cated analysis focusing primarily on the setting of re-
irradiation and the use of particle therapy for recurrent
meningioma and featuring a comparable cohort size.
Conclusion
Particle therapy applied as re-irradiation in recurrent
meningiomas is a feasible method of achieving good
local control at moderate toxicity. Improved dose
conformity and thus the reduction of integral dose to
OAR potentially leads to substantial clinical benefits. In
addition, carbon ions provide an increased relative bio-
logical effectiveness, which could be beneficial to tumor
control. A longer follow-up and prospective clinical
studies on a larger number of patients are necessary to
more accurately validate the real value of particle re-
irradiation in recurrent meningiomas.
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